Abstract
The aryl hydrocarbon receptor (AhR)3 is a ligand-activated transcription factor that forms a functional heterodimeric complex with the AhR nuclear translocator (Arnt) protein. The environmental toxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), is a high affinity ligand for the AhR and has been extensively used to investigate AhR-mediated biochemical and toxic responses. TCDD modulates several endocrine pathways including inhibition of 17β-estradiol-induced responses in the immature and ovariectomized rodent uterus and mammary gland and in human breast cancer cell lines. TCDD inhibits formation and growth of mammary tumors in carcinogen-induced rodent models and relatively nontoxic selective AhR modulators (SAhRMs) are being developed for treatment of breast cancer. The mechanisms of inhibitory AhR-estrogen receptor (ER) crosstalk have been investigated in MCF-7 breast cancer cells by analysis of promoter regions of genes induced by E2 and inhibited by TCDD. AhR-mediated inhibition of E2-induced cathepsin D, pS2, c-fos, and heat shock protein 27 gene expression involves direct interaction of the AhR complex with inhibitory pentanucleotide (GCGTG) dioxin responsive elements (iDREs) resulting in disruption of interactions between proteins binding DNA elements required for ER action and the basal transcription machinery. Mechanisms of inhibitory AhR-ER crosstalk indicate that functional iDREs are required for inhibition of some genes; however, results indicate that other interaction pathways are important including AhR-mediated proteasome-dependent degradation of the ER.
Similar content being viewed by others
REFERENCES
E. J. Sondik (1994). Breast cancer trends. Incidence, mortality, and survival. Cancer 74:995–999.
B. S. Hulka, E. T. Liu, and R. A. Lininger (1994). Steroid hormones and risk of breast cancer. Cancer 74:1111–1124.
B. S. Hulka (1997). Epidemiologic analysis of breast and gynecologic cancers. In M. Aldaz, M. N. Gould, J. McLachlan, and T. J. Slaga (eds.), Etiology of Breast and Gynecological Cancers, Wiley-Liss, Inc., pp. 17–29.
J. Russo and I. H. Russo (1997). Toward a unified concept of mammary carcinogenesis. In M. Aldaz, M. N. Gould, J. McLachlan, and T. J. Slaga (eds.), Etiology of Breast and Gynecological Cancers, Wiley-Liss, Inc., pp. 1–16.
V. C. Jordan (1994). Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat. 31:41–52.
S. Safe (1995). Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Therap. 67:247–281.
T. Zacharewski and S. Safe (1998). Antiestrogenic activity of TCDD and related compounds. In K. S. Korach (ed.), Reproductive and Developmental Toxicology, Marcel Dekker, Inc., New York, pp. 431–448.
W. Porter and S. Safe (1998). Estrogenic and antiestrogenic compounds. In A. Puga and K. B. Wallace (eds.), Molecular Biology Approaches to Toxicology, Techbooks, Fairfax, Virginia, pp. 267–283.
S. Safe (1999). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related environmental antiestrogens: Characterization and mechanism of action. In R. K. Naz (ed.), Endocrine Disruptors, CRC Press, Boca Raton, Florida, pp. 187–221.
S. Safe, C. Qin, and A. McDougal (1999). Development of selective aryl hydrocarbon receptor modulators (SARMs) for treatment of breast cancer. Expert Opin. Invest. Drugs 8:1385–1396.
A. Poland, E. Glover, and A. S. Kende (1976). Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol: Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 251:4936–4946.
A. Poland and J. C. Knutson (1982). 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons. Examinations of the mechanism of toxicity. Ann. Rev. Pharmacol. Toxicol. 22:517–554.
R. M. Evans (1988). The steroid and thyroid hormone receptor superfamily. Science 240:889–895.
M. Ema, K. Sogawa, N. Watanabe, Y. Chujoh, N. Matsushita, O. Gotoh, Y. Funae, and Y. Fujii-Kuriyama (1992). cDNA cloning and structure of the putative Ah receptor. Biochem. Biophys. Res. Commun. 184:246–253.
K. M. Burbach, A. B. Poland, and C. A. Bradfield (1992). Cloning of the Ah-receptor cDNA reveals a distinctive ligandactivated transcription factor. Proc. Natl. Acad. Sci. U.S.A 89:8185–8189.
E. C. Hoffman, H. Reyes, F.-F. Chu, F. Sander, L. H. Conley, B. A. Brooks, and O. Hankinson (1991). Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954–958.
C. L. Wilson and S. Safe (1998). Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol. Pathol. 26:657–671.
M. R. Probst and O. Hankinson (1999). Interactions of ARNT with AhR and HIF-1α. In A. Puga and K. B. Wallace (eds.), Molecular Biology of the Toxic Response, Taylor and Francis, Philadelphia, pp. 377–392.
C. C. Abnet, R. L. Tanguay, M. E. Hahn, W. Heideman, and R. E. Peterson (1999). Two forms of aryl hydrocarbon receptor type 2 in rainbow trout (Oncorhynchus mykiss). Evidence for differential expression and enhancer specificity. J. Biol. Chem. 274:15159–15166.
E. Maltepe, J. V. Schmidt, D. Baunoch, C. A. Bradfield, and M. C. Simon (1997). Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403–407.
P. Fernandez-Salguero, T. Pineau, D. M. Hilbert, T. McPhail, S. S. Lee, S. Kimura, D. W. Nebert, S. Rudikoff, J. M. Ward, and F. J. Gonzalez (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268:722–726.
J. V. Schmidt, G. H. Su, J. K. Reddy, M. C. Simon, and C. A. Bradfield (1996). Characterization of a murine Ahr null allele: Involvement of theAhreceptor in hepatic growth and development. Proc. Natl. Acad. Sci. U.S.A. 93:6731–6736.
J. P. Whitlock, S. T. Okino, L. Dong, H. P. Ko, R. Clarke-Katzenberg, Q. Ma, and H. Li (1996). Induction of cytochrome P4501A1: A model for analyzing mammalian gene transcription. FASEB J. 10:809–818.
A. Kobayashi, K. Numayamatsuruta, K. Sogawa, and Y. Fujii-Kuriyama (1997). CBP/p300 functions as a possible transcriptional coactivator of Ah receptor nuclear translocator (Arnt). J. Biochem. 122:703–710.
T. A. Nguyen, D. Hoivik, J. E. Lee, and S. Safe (1999). Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch. Biochem. Biophys. 367:250–257.
M. B. Kumar, R. W. Tarpey, and G. H. Perdew (1999). Differential recruitment of coactivator RIP140 by Ah and estrogen receptors: Absence of a role for LXXLL motifs. J. Biol. Chem. 274:22155–22164.
R. J. Kociba, D. G. Keyes, J. E. Beger, R. M. Carreon, C. E. Wade, D. A. Dittenber, R. P. Kalnins, L. E. Frauson, C. L. Park, S. D. Barnard, R. A. Hummel, and C. G. Humiston (1978). Results of a 2-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicol. Appl. Pharmacol. 46:279–303.
M. Holcomb and S. Safe (1994). Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett. 82:43–47.
A. M. Tritscher, G. C. Clark, C. Sewall, R. C. Sills, R. Maronpot, and G. W. Lucier (1995). Persistence of TCDD-induced hepatic cell proliferation and growth of enzyme altered foci after chronic exposure followed by cessation of treatment in DEN initiated female rats. Carcinogenesis 16:2807–2811.
R. Bannister, L. Biegel, D. Davis, B. Astroff, and S. Safe (1989). 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL/6 mice. Toxicology 54:139–150.
C. Yao and S. Safe (1989). 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced porphyria in genetically inbred mice: Partial antagonism and mechanistic studies. Toxicol. Appl. Pharmacol. 100:208–216.
B. Astroff, T. Zacharewski, S. Safe, M. P. Arlotto, A. Parkinson, P. Thomas, and W. Levin (1988). 6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: Inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. Mol. Pharmacol. 33:231–236.
B. Astroff and S. Safe (1991). 6-Alkyl-1,3,8-trichlorodibenzofurans as antiestrogens in female Sprague-Dawley rats. Toxicology 69:187–197.
T. Zacharewski, M. Harris, L. Biegel, V. Morrison, M. Merchant, and S. Safe (1992). 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: Evidence for the role of the Ah receptor. Toxicol. Appl. Pharmacol. 13:311–318.
R. Dickerson, L. Howie-Keller, and S. Safe (1995). Alkyl polychlorinated dibenzofurans and related compounds as anties trogens in the female rat uterus: Structure-activity studies. Toxicol. Appl. Pharmacol. 135:287–298.
G. Sun and S. Safe (1997). Antiestrogenic activities of alternate substituted polychlorinated dibenzofurans in MCF-7 human breast cancer cells. Cancer Chemotherapy Pharmacol. 40:239–244.
A. McDougal, C. Wilson, and S. Safe (1997). Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett. 120:53–63.
L. F. Bjeldanes, J. Y. Kim, K. R. Grose, J. C. Bartholomew, and C. A. Bradfield (1991). Aromatic hydrocarbon responsivenessreceptor agonists generated from indole-3-carbinol in vitro and in vivo—comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. U.S.A. 88:9543–9547.
I. Chen, S. Safe, and L. Bjeldanes (1996). Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem. Pharmacol. 51:1069–1076.
I. Chen, A. McDougal, F. Wang, and S. Safe (1998). Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19:1631–1639.
S. M. Hyder, C. Chiappetta, L. Murthy, and G. M. Stancel (1997). Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 57:2547–2549.
J. Z. Yang and W. G. Foster (1997). Continuous exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin inhibits the growth of surgically induced endometriosis in the ovariectomized mouse treated with high dose estradiol. Toxicol. Ind. Health 13:15–25.
G. W. Lucier, A. Tritscher, T. Goldsworthy, J. Foley, G. Clark, J. Goldstein, and R. Maronpot (1991). Ovarian hormones enhance 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated increases in cell proliferation and preneoplastic foci in a two-stage model for rat hepatocarcinogenesis. Cancer Res. 51:1391–1397.
A. M. Tritscher, A. M. Seacat, J. D. Yager, J. D. Groopman, B. D. Miller, D. Bell, T. R. Sutter, and G. W. Lucier (1996). Increased oxidativeDNAdamage in livers of 2,3,7,8-tetrachlorodibenzo-p-dioxin treated intact but not ovariectomized rats. Cancer Lett. 98:219–225.
N. M. Brown, P. A. Manzolillo, J. X. Zhang, J. Wang, and C. A. Lamartiniere (1998). Prenatal TCDD and predisposition to mammary cancer in the rat. Carcinogenesis 19:1623–1629.
J. F. Gierthy, D. W. Lincoln, M. B. Gillespie, J. I. Seeger, H. L. Martinez, H. W. Dickerman, and S. A. Kumar (1987). Suppression of estrogen-regulated extracellular plasminogen activator activity of MCF-7 cells by 2,3,7,8-tetrachlorodibenzop-dioxin. Cancer Res. 47:6198–6203.
J. F. Gierthy and D. W. Lincoln. (1988). Inhibition of postcon-fluent focus production in cultures of MCF-7 breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Breast Cancer Res. Treat. 12:227–233.
L. Biegel and S. Safe (1990). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52-and 160-kDa proteins in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 37:725–732.
V. Krishnan and S. Safe (1993). Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: Quantitative structure-activity relationships. Toxicol. Appl. Pharmacol. 120:55–61.
V. Krishnan, T. R. Narasimhan, and S. Safe (1992). Development of gel staining techniques for detecting the secretion of procathepsin D (52-kDa protein) in MCF-7 human breast cancer cells. Anal. Biochem. 204:137–142.
V. Krishnan, W. Porter, M. Santostefano, X. Wang, and S. Safe (1995). Molecular mechanism of inhibition of estrogeninduced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell. Biol. 15:6710–6719.
M. Moore, T. R. Narasimhan, X. Wang, V. Krishnan, S. Safe, H. J. Williams, and A. I. Scott (1993). Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-tetradecanoylphorbol-13-acetate (TPA) and 17β-estradiol in MCF-7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 44:251–261.
T. R. Narasimhan, S. Safe, H. J. Williams, and A. I. Scott (1991). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced glucose metabolism in MCF-7 human breast cancer cells: 13C-nuclear magnetic resonance studies. Mol. Pharmacol. 40:1029–1035.
T. R. Zacharewski, K. L. Bondy, P. McDonell, and Z. F. Wu (1994). Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced pS2 expression. Cancer Res. 54:2707–2713.
Y.-F. Lu, G. Sun, X. Wang, and S. Safe (1996). Inhibition of prolactin receptor gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 human breast cancer cells. Arch. Biochem. Biophys. 332:35–40.
W. Wang, R. Smith, and S. Safe (1998). Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: Modulation of hormone-induced cell cycle enzymes. Arch. Biochem. Biophys. 356:239–248.
M. Harris, T. Zacharewski, and S. Safe (1990). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds on the occupied nuclear estrogen receptor in MCF-7 human breast cancer cells. Cancer Res. 50:3579–3584.
X. Wang, W. Porter, V. Krishnan, T. R. Narasimhan, and S. Safe (1993). Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol. Cell. Endocrinol. 96:159–166.
M. Moore, X. Wang, Y.-F. Lu, M. Wormke, A. Craig, J. Gerlach, R. Burghardt, and S. Safe (1994). Benzo[a]pyrene resistant (BaPR) human breast cancer cells: A unique aryl hydrocarbon (Ah)-nonresponsive clone. J. Biol. Chem. 269:11751–11759.
I. Kharat and F. Saatcioglu (1996). Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. J. Biol. Chem. 271:10533–10537.
C. M. Klinge, K. Kaur, and H. I. Swanson (2000). The aryl hydrocarbon receptor interacts with estrogen receptor α and orphan receptors COUP-TFI and ERRα1. Arch. Biochem. Biophys. 373:163–174.
Z. Nawaz, D. M. Lonard, A. P. Dennis, C. L. Smith, and B. W. O'Malley (1999). Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 96:1858–1862.
N. A. Davarinos and R. S. Pollenz (1999). Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J. Biol. Chem. 274:28708–28715.
I. Chen, T. Hsieh, T. Thomas, and S. Safe (2000). Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in MCF-7 breast cancer cells: Identification of genes downregulated by AhR agonists using suppression subtractive hybridization. Gene (in press).
W. Porter, B. Saville, D. Hoivik, and S. Safe (1997). Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 11:1569–1580.
R. Duan, W. Porter, and S. Safe (1998). Estrogen-induced cfos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139:1981–1990.
F. Wang, D. Hoivik, R. Pollenz, and S. Safe (1998). Functional and physical interactions between the estrogen receptor-Sp1 and the nuclear aryl hydrocarbon receptor complexes. Nucleic Acids Res. 26:3044–3052.
G. Sun, W. Porter, and S. Safe (1998). Estrogen-induced retinoic acid receptor α1 gene expression: Role of estrogen receptor-Sp1 complex. Mol. Endocrinol. 12:882–890.
W. Xie, R. Duan, and S. Safe (1999). Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: Role of estrogen receptor-Sp1 interactions. Endocrinology 140:219–227.
C. Qin, P. Singh, and S. Safe (1999). Transcriptional activation of insulin-like growth factor binding protein 4 by 17β-estradiol in MCF-7 cells: Role of estrogen receptor-Sp1 complexes. Endocrinology 140:2501–2508.
W. Wang, L. Dong, B. Saville, and S. Safe (1999). Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol. 13:1373–1387.
B. Gillesby, M. Santostefano, W. Porter, Z. F. Wu, S. Safe, and T. Zacharewski (1997). Identification of a motif within the 5'-regulatory region on pS2 which is responsible for Ap1 binding and TCDD-mediated suppression. Biochemistry 36:6080–6089.
A. D. Johnson (1995). The price of repression. Cell 81:655–658.
R. Duan, W. Porter, I. Samudio, C. Vyhlidal, M. Kladde, and S. Safe (1999). Transcriptional activation of c-fos protooncogene by 17β-estradiol: Mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol. Endocrinol. 13:1511–1521.
K. Ramamoorthy, M. S. Gupta, G. Sun, A. McDougal, and S. H. Safe (1999). 3,3',4,,4'-Tetrachlorobiphenyl exhibits antiestrogenic and antitumorigenic activity in the rodent uterus and mammary and in human breast cancer cells. Carcinogenesis 20:115–123.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Safe, S., Wormke, M. & Samudio, I. Mechanisms of Inhibitory Aryl Hydrocarbon Receptor-Estrogen Receptor Crosstalk in Human Breast Cancer Cells. J Mammary Gland Biol Neoplasia 5, 295–306 (2000). https://doi.org/10.1023/A:1009550912337
Issue Date:
DOI: https://doi.org/10.1023/A:1009550912337